Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023

Eight presentations highlight the differentiated profile and broad applicability of the company’s HSC gene therapy platform

Data from proof-of-concept study of OTL-203 in MPS-IH demonstrate favorable outcomes for clinical manifestations of the disease not well addressed by the current standard-of-care